Sucampo Pharma (SCMP) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sucampo Reports Fourth Quarter and Full Year 2014 Financial Results and Corporate Update
March 4, 2015 6:30 AM ESTStrong Year-over-Year Revenue and Sales Growth for AMITIZA Significant Progress on Pipeline Programs and Strategic Plan Net Income and EPS Excluding Special Items in Line with 2014 Guidance Sucampo Provides 2015 Earnings Guidance Company to host conference call today at 8:30 am Eastern
BETHESDA, Md., March 4, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq: SCMP) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2014.
For the fourth quarter of 2014, Sucampo... More
